Clinical trial
Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys
NCT00133354 · Nemours Children's Clinic, Other · Completed
Key facts
| NCT number | NCT00133354 |
|---|---|
| Title | Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys |
| Official title | Double-blind Trial Investigating the Safety and Efficacy of the Inhibitor Anastrozole (ARIMIDEX) in Delaying Epiphyseal Fusion and Increasing Height Potential of Adolescent Males With Growth Hormone (GH) Deficiency |
| Lead sponsor | Nemours Children's Clinic, Other |
| Collaborators | AstraZeneca Industry Genentech, Inc. EMD Serono |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Hypopituitarism |
| Intervention type | Drug |
| Interventions | Arimidex (Anastrozole), Placebo, Growth Hormone |
| Enrollment | 53 |
| Start date | Nov 1, 2001 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2010 |
| First posted | Aug 23, 2005 |
| Last update posted | Oct 12, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: